5PSQ-042 Modification on fasting lipid and renal parameters in patients switching from tenofovir disoproxil to tenofovir alafenamide

BackgroundTenofovir alafenamide (TAF) in clinical trials demonstrated less impact than tenofovir disoproxil (TDF) in affecting renal and bone parameters, whereas TDF protects from hypercholesterolaemia and hypertriglyceridaemia.PurposeTo analyse in clinical practice of human immunodeficiency virus-infected (HIV-infected), how renal function and fasting lipid parameters are modified when switching TDF to TAF. As a second aim, to evaluate effectiveness and the immunological system.Material and methodsRetrospective observational study (July 2016 to August 2018) conducted in HIV-infected patients treated for ≥6 months with a TDF regimen who switched to a TAF regimen kept >48 weeks. We considered virological success if HIV-1 RNA 0.05). There were no statistical differences with GFR (p>0.05).Cholesterol correlated with LDL (p=0.0001; r=0.94), but not with HDL (p>0.05; r=0.03).All patients achieved virological success, even three patients with RNA-concentration >35 copies/mL before switching.ConclusionAfter 48 weeks of patients, in clin